Subscribe to RSS
Clinical outcome of endoscopic therapy in patients with symptomatic pancreas divisum: a Dutch cohort study
Background and study aims Although the majority of patients with pancreas divisum (PDiv) are asymptomatic, a subgroup present with recurrent pancreatitis or pain for which endoscopic therapy may be indicated. The aim of this study was to evaluate success rates and long-term outcomes of endoscopic treatment in patients with symptomatic PDiv.
Patients and methods A multicenter, retrospective cohort study was performed. Patients with symptomatic PDiv presenting with recurrent acute pancreatitis (RAP), chronic pancreatitis (CP), or chronic abdominal pancreatic-type pain (CAP) who underwent endoscopic retrograde cholangiopancreatography (ERCP) between January 2000 and December 2019 were included. The primary outcome was clinical success, defined as either no recurrent episode of acute pancreatitis (AP) for RAP patients, no flares for CP patients, or absence of abdominal pain for patients with CAP after technically successful ERCP.
Results In 60 of 81 patients (74.1 %) a technically successful papilla minor intervention was performed. Adverse events were reported in 30 patients (37 %), with post-ERCP pancreatitis in 18 patients. The clinical success rate for patients with at least 3 months of follow-up was 42.6 %, with higher rates of success among patients presenting with RAP (44.4 %) as compared to those with CP (33.3 %) or CAP (33.3 %). Long-term sustained response was present in 40.9 % of patients with a technically successful intervention. In patients with RAP who did not completely respond to treatment, the mean number of AP episodes after treatment decreased significantly from 3.5 to 1.1 per year, and subsequently the interval between AP episodes increased from 278 to 690 days (P = 0.0006). A potential predictive factor of failure of clinical success after technically successful ERCP, at univariate analysis, was male sex (OR = 0.25, P = 0.02).
Conclusions Endoscopic therapy in patients with symptomatic PDiv is moderately effective, with its highest yield in patients presenting with RAP. Future studies are needed to assess factors predictive for success of endoscopic therapy and potential risk factors for relapse after ERCP.
Received: 09 December 2020
Accepted: 15 February 2021
21 June 2021 (online)
© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Bulow R, Simon P, Thiel R. et al. Anatomic variants of the pancreatic duct and their clinical relevance: an MR-guided study in the general population. Eur Radiol 2014; 24: 3142-3149
- 2 Adibelli ZH, Adatepe M, Imamoglu C. et al. Anatomic variations of the pancreatic duct and their relevance with the Cambridge classification system: MRCP findings of 1158 consecutive patients. Radiol Oncol 2016; 50: 370-377
- 3 Dimitriou I, Katsourakis A, Nikolaidou E. et al. The main anatomical variations of the pancreatic duct system: review of the literature and its importance in surgical practice. J Clin Med Res 2018; 10: 370-375
- 4 Kozu T, Suda K, Toki F. Pancreatic development and anatomical variation. Gastrointest Endosc Clin N Am 1995; 5: 1-30
- 5 Gupta A, Rai P, Singh V. et al. Intrahepatic biliary duct branching patterns, cystic duct anomalies, and pancreas divisum in a tertiary referral center: A magnetic resonance cholangiopancreaticographic study. Indian J Gastroenterol 2016; 35: 379-384
- 6 Bernard JP, Sahel J, Giovannini M. et al. Pancreas divisum is a probable cause of acute pancreatitis: a report of 137 cases. Pancreas 1990; 5: 248-254
- 7 Cotton PB. Congenital anomaly of pancreas divisum as cause of obstructive pain and pancreatitis. Gut 1980; 21: 105-114
- 8 Hafezi M, Mayschak B, Probst P. et al. A systematic review and quantitative analysis of different therapies for pancreas divisum. Am J Surg 2017; 214: 525-537
- 9 Liao Z, Gao R, Wang W. et al. A systematic review on endoscopic detection rate, endotherapy, and surgery for pancreas divisum. Endoscopy 2009; 41: 439-444
- 10 Lans JI, Geenen JE, Johanson JF. et al. Endoscopic therapy in patients with pancreas divisum and acute pancreatitis: a prospective, randomized, controlled clinical trial. Gastrointest Endosc 1992; 38: 430-434
- 11 Michailidis L, Aslam B, Grigorian A. et al. The efficacy of endoscopic therapy for pancreas divisum: a meta-analysis. Ann Gastroenterol 2017; 30: 550-558
- 12 Schneider A, Lohr JM, Singer MV. The M-ANNHEIM classification of chronic pancreatitis: introduction of a unifying classification system based on a review of previous classifications of the disease. J Gastroenterol 2007; 42: 101-119
- 13 Borak GD, Romagnuolo J, Alsolaiman M. et al. Long-term clinical outcomes after endoscopic minor papilla therapy in symptomatic patients with pancreas divisum. Pancreas 2009; 38: 903-906
- 14 Kanth R, Samji NS, Inaganti A. et al. Endotherapy in symptomatic pancreas divisum: a systematic review. Pancreatology 2014; 14: 244-250
- 15 Sarr MG, Banks PA, Bollen TL. et al. The new revised classification of acute pancreatitis 2012. Surg Clin North Am 2013; 93: 549-562
- 16 Tringali A, Voiosu T, Schepis T. et al. Pancreas divisum and recurrent pancreatitis: long-term results of minor papilla sphincterotomy. Scand J Gastroenterol 2019; 54: 359-364
- 17 Gutta A, Fogel E, Sherman S. Identification and management of pancreas divisum. Expert Rev Gastroenterol Hepatol 2019; 13: 1089-1105
- 18 Cheng CL, Sherman S, Watkins JL. et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101: 139-147
- 19 Freeman ML, DiSario JA, Nelson DB. et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54: 425-434